Trial
NCT00124579
S0417 Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
SWOG Cancer Research Network
Collaborators
National Cancer Institute (NCI)
Condition
Multiple Myeloma
Intervention
bortezomib
Why stopped
poor accrual
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2018-08-09